title: Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry InhibitorsIn VitroandEx Vivo.
abstract: A hepatitis C virus (HCV) epidemic affecting HIV-infected men who have sex with men (MSM) is expanding worldwide. In spite of the improved cure rates obtained with the new direct-acting antiviral drug (DAA) combinations, the high rate of reinfection within this population calls urgently for novel preventive interventions. In this study, we determined in cell culture andex vivoexperiments with human colorectal tissue that lipoquads, G-quadruplex DNA structures fused to cholesterol, are efficient HCV pangenotypic entry and cell-to-cell transmission inhibitors. Thus, lipoquads may be promising candidates for the development of rectally applied gels to prevent HCV transmission.
authors.affiliation: Molecular Virology Group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
authors.forename: George
authors.initials: G
authors.lastname: Koutsoudakis
authors.affiliation: Molecular Virology Group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
authors.forename: Alexia
authors.initials: A
authors.lastname: Paris de León
authors.affiliation: Section of Virology, Faculty of Medicine, St. Mary's Campus, Imperial College London, London, United Kingdom.
authors.forename: Carolina
authors.initials: C
authors.lastname: Herrera
authors.affiliation: Section of Virology, Faculty of Medicine, St. Mary's Campus, Imperial College London, London, United Kingdom.
authors.forename: Marcus
authors.initials: M
authors.lastname: Dorner
authors.affiliation: Molecular Virology Group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
authors.forename: Gemma
authors.initials: G
authors.lastname: Pérez-Vilaró
authors.affiliation: AIDS Research Group, Institut D'Investigacions Biomèdics August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Lyonnais
authors.affiliation: Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) and Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.
authors.forename: Santiago
authors.initials: S
authors.lastname: Grijalvo
authors.affiliation: Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) and Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.
authors.forename: Ramon
authors.initials: R
authors.lastname: Eritja
authors.affiliation: Infection Biology Group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.|ICREA, Barcelona, Spain.
authors.forename: Andreas
authors.initials: A
authors.lastname: Meyerhans
authors.affiliation: AIDS Research Group, Institut D'Investigacions Biomèdics August Pi i Sunyer (IDIBAPS), Barcelona, Spain.|Faculté de Biologie, Sorbonne Universités, UPMC Université Paris 06, Paris, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Mirambeau
authors.affiliation: Molecular Virology Group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain juana.diez@upf.edu.
authors.forename: Juana
authors.initials: J
authors.lastname: Díez
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002784:Cholesterol / Q000737:chemistry / Q000627:therapeutic use*; D054856:G-Quadruplexes; D057809:HEK293 Cells; D015658:HIV Infections; D016174:Hepacivirus / Q000187:drug effects* / Q000254:growth & development; D006526:Hepatitis C / Q000188:drug therapy* / Q000635:transmission*; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D009841:Oligonucleotides / Q000737:chemistry / Q000627:therapeutic use*; D053586:Virus Internalization / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D009841:Oligonucleotides; D002784:Cholesterol
keywords: DNA G-quadruplex structures; HCV cell-to-cell inhibitor; HCV entry inhibitor; HCV pangenotypic inhibitor; antiviral treatment; oligonucleotide-cholesterol conjugates